Heartflow, Inc.

n

Insider Trading Arrangements

During the quarter ended June 30, 2026, two of our directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended)adopted, modified orterminated a “Rule 10b5-1 (c) trading arrangement” or a “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K as follows:

On June 4, 2026, Vikram Verghese, our Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 106,982 shares of our common stock. The duration of the trading arrangement is until December 31, 2026, or earlier if all transactions under the trading arrangement are completed. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c).

On June 16, 2026, Campbell D.K. Rogers, M.D., our Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 91,746 shares of our common stock. The duration of the trading arrangement is until December 18, 2026, or earlier if all transactions under the trading arrangement are completed. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c).

In addition, in Item 9B of Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, we inadvertently omitted the disclosure of a new Rule 10b5-1 trading arrangement entered into by Campbell D.K. Rogers, M.D. on December 12, 2025, which provided for the sale from time to time of an aggregate of up to 27,657 shares of our common stock. The duration of the trading arrangement is until August 31, 2026, or earlier if all transactions under the trading arrangement are completed. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c).

‎

Item 6. Exhibit Inde